**Specifications table**TableSubject area*Medicine*More specific subject area*Cardiology-imaging*Type of data*figure, Table*How data was acquired*Prospective single-center cross-sectional*Data format*Raw and analyzed*Experimental factors*Coronary angiography, Optical coherence tomography, Flow cytometry, Continuous glucose monitoring*Experimental features*Association between arteriosclerosis promoting factor and coronary artery plaque assessed by optical coherence tomography*Data source location*Kobe, Japan*Data accessibility*Data are within this article*

**Value of the data**•Patients population enrolled in our research [@bib1].•Diagnostic ability of CD14^++^CD16^+^ monocytes to identify thin-cap fibroatheromas using receiver operating characteristics curves.•Association between laboratory variables and plaque properties assessed by optical coherence tomography.

1. Data {#s0005}
=======

All the data shown in this article are supplementary data of our research [@bib1]. [Fig. 1](#f0005){ref-type="fig"} shows flow of study population. [Fig. 2](#f0010){ref-type="fig"} presents the area under the curve (AUC) to predict thin-cap fibroatheroma. [Table 1](#t0005){ref-type="table"} presents variables measured by the continuous glucose monitoring system. Among total 50 patients, continuous glucose monitoring analysis was performed in 46 patients due to its poor image quality in 4 patients. [Table 2](#t0010){ref-type="table"} shows association between laboratory variables and plaque properties.Fig. 1Study population. CKD = chronic kidney disease; LVEF = left ventricular ejection fraction; CGM = continuous glucose monitoring.Fig. 1Fig. 2ROC curves for prediction of TCFA. ROC for CD14^++^CD16^+^ monocytes was computed for the prediction of TCFA. ROC = receiver operating characteristic; TCFA = thin-cap fibroatheroma.Fig. 2Table 1Variables measured by the continuous glucose monitoring system.Table 1**Total N = 46Tertile 1** (CD14^++^CD16^+^ monocyte \< 13.6) **N = 16Tertile 2** (13.6 ≦ CD14^++^CD16^+^ monocyte \< 18.3) **N = 14Tertile 3** (18.3 ≦ CD14^++^CD16^+^ monocyte) **N = 16*****P*****value**MAGE, mg/dl64.6 ± 17.356.9 ± 18.665.1 ± 17.072.0 ± 13.50.046Mean blood glucose, mg/dl128.9 ± 24.9125.0 ± 23.4131.4 ± 28.0130.5 ± 24.70.74Max blood glucose, mg/dl220.2 ± 54.2201.3 ± 60.4225.6 ± 57.9234.3 ± 40.40.22Min blood glucose, mg/dl77.4 ± 25.082.8 ± 27.873.0 ± 25.675.9 ± 21.90.60Time in hyperglycemia, %32.8 ± 29.727.9 ± 33.333.7 ± 30.137.0 ± 26.60.70Time in hypoglycemia, %3.65 ± 12.81.4 ± 3.82.4 ± 4.87.0 ± 20.90.43[^1]Table 2Pearson correlation coefficients.Table 2CD14^++^CD16^+^ monocytesCRPLDL cholesterolHDL cholesterolHbA1cMAGELesion length0.040.0020.12−0.100.070.16Lipid length0.18-0.070.15−0.130.160.28\*Max lipid arch0.34\*-0.170.81−0.080.150.34\*Mean lipid arch0.34\*-0.13-0.16−0.040.150.36\*Lipid index0.24-0.100.07−0.110.190.35\*Calcification length−0.0040.050.190.090.03−0.02Mean calcification arch−0.18-0.020.20−0.005−0.28−0.29Calcification index−0.13-0.0080.190.08−0.07−0.11Fibrous cap thickness−0.51\*0.100.090.13−0.19−0.25[^2]

2. Experimental design, materials and methods {#s0010}
=============================================

Our research article entitled "Impact of CD14^++^CD16^+^ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients" was a cross-sectional research from single-center prospective registry. Patients admitted with stable coronary artery disease who had undergone coronary angiography were enrolled at Kobe university hospital ([Fig. 1](#f0005){ref-type="fig"}). Patients were excluded if they had renal disease (serum creatinine \>2.0 mg/dl), low left ventricular ejection fraction (\<45%), active infection, inflammatory arthritis, connective tissue disease and malignancies.

Data of coronary angiography, optical coherence tomography, flow cytometry, continuous glucose monitoring was obtained according to the method section of our research [@bib1]. For statistical correlation between two parameters, simple linear correlations were calculated using the method of least squares and by determining the Pearson\'s correlation coefficient. The AUC was calculated to predict TCFA, with AUC = 0.50 representing no accuracy and AUC = 1.00 indicating maximum accuracy. Analyses were performed using SPSS version 24 (IBM Corp., Armonk, New York). Values of *P* \< 0.05 were considered statistically significant.

Transparency document. Supplementary material {#s0020}
=============================================

Supplementary material.

None.

Transparency data associated with this article can be found in the online version at [doi:10.1016/j.dib.2018.03.022](https://doi.org/10.1016/j.dib.2018.03.022){#ir0005}.

[^1]: Values are mean ± SD. MAGE = mean amplitude of glycemic excursion.

[^2]: Values are r values. Association between laboratory variables and plaque properties. \**P* \< 0.05. CRP = C-reactive protein; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MAGE = mean amplitude of glycemic excursion.
